Figure 2.
Predicted drug resistance to current ART and future treatment options in treated patients. “Current therapies” to the left of the dashed line, refers to medications taken by participants at the time of the study; “Future therapies” to the right of the dashed line refers to potentially available subsequent second-line RT inhibitor options at the time of the study. Bars show percent of plasma sequences with predicted resistance according to four categories, based on resistance scores available at the Stanford HIV Sequence Database [56]. 3TC, lamivudine; D4T, stavudine; AZT, zidovudine; NVP, nevirapine; EFV, efavirenz; ABC, abacavir; DDI, didanosine; TDF, tenofovir; RPV, rilpivirine; ETR, etravirine.